Evidence map›Paper›PMID 25502518›Full record

ArticlePloS one2014

Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.

David M Baron, Ulrike Kaindl, Verena J Haudek-Prinz, Editha Bayer, Clemens Röhrl, Christopher Gerner, Brigitte Marian

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David M BaronDepartment of Medicine I, Clinic for Internal Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria; Department of Anesthesia, General Intensive Care, and Pain Management Medical, Medical University of Vienna, Vienna, Austria.
Ulrike KaindlDepartment of Medicine I, Clinic for Internal Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.
Verena J Haudek-PrinzInstitute of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Editha BayerDepartment of Medicine I, Clinic for Internal Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.
Clemens RöhrlDepartment of Medicine I, Clinic for Internal Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.
Christopher GernerInstitute of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Brigitte MarianDepartment of Medicine I, Clinic for Internal Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is a leading cause of mortality worldwide. Resistance to therapy is common and often results in patients succumbing to the disease. The mechanisms of resistance are poorly understood. Cells basically have two possibilities to survive a treatment with potentially apoptosis-inducing substances. They can make use of their existing proteins to counteract the induced reactions or quickly upregulate protective factors to evade the apoptotic signal. To identify protein patterns involved in resistance to apoptosis, we studied two colorectal adenocarcinoma cell lines with different growth responses to low-molar concentrations of the thiazolidinedione Ciglitazone: HT29 cells underwent apoptosis, whereas SW480 cells increased cell number. Fluorescence detection and autoradiography scans of 2D-PAGE gels were performed in both cell lines to assess protein synthesis and turnover, respectively. To verify the data we performed shotgun analysis using the same treatment procedure as in 2D-experiments. Biological functions of the identified proteins were mainly associated with apoptosis regulation, chaperoning, intrinsic inflammation, and DNA repair. The present study suggests that different growth response of two colorectal carcinoma cell lines after treatment with Ciglitazone results from cell-specific protein synthesis and differences in protein regulation.

Indexed as

AdenocarcinomaAntineoplastic AgentsApoptosisCell CycleCell Line, TumorCell SurvivalColorectal NeoplasmsHumansPPAR gammaProtein BiosynthesisThiazolidinedionesAntineoplastic AgentsciglitazonePPAR gammaThiazolidinediones

Identifiers

PMID25502518
PMCPMC4263530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.